Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ARG1 | P05089 | 2/20 | 0.36 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.36 |
| ▸ | IL1B | P01584 | 1/20 | 0.30 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3085448 | 0.83 | MALT1 (0.42) | ARG1MALT1IL1BP2RX7 | |
| SCHEMBL21681172 | 0.83 | MALT1 (0.42) | ARG1MALT1IL1BP2RX7 | |
| Hydrochloric Acid SCHEMBL19056470 | 0.81 | MALT1 (0.41) | ARG1MALT1IL1BP2RX7 | |
| SCHEMBL19059588 | 0.81 | ARG1 (0.36) | ARG1MALT1 | |
| SCHEMBL16771700 | 0.77 | ARG1 (0.38) | ARG1MALT1 | |
| SCHEMBL4666386 | 0.77 | ARG1 (0.38) | ARG1MALT1 | |
| SCHEMBL16771693 | 0.77 | ARG1 (0.38) | ARG1MALT1 | |
| Hydrochloric Acid SCHEMBL16759537 | 0.76 | ARG1 (0.38) | ARG1MALT1 | |
| Hydrochloric Acid SCHEMBL18259318 | 0.76 | ARG1 (0.38) | ARG1MALT1 | |
| Hydrochloric Acid SCHEMBL15573124 | 0.76 | ARG1 (0.38) | ARG1MALT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3426664-B1 | SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-06-30 | — | — | EP | disclosed |
| US-10898504-B2 | Substituted nucleoside analogues for use as PRMT5 inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2021-01-26 | — | — | US | disclosed |
| US-20200289539-A1 | NOVEL SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200289539-A1 | NOVEL SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | PRMT5, PRMT1, PRMT3 | ARG1 65/4885MALT1 4299/4885IL1B 4398/4885 |
| US-10898504-B2 | Substituted nucleoside analogues for use as PRMT5 inhibitors | PRMT5, PRMT1, PRMT3 | ARG1 105/4885MALT1 4277/4885IL1B 4413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.